Method for purifying ziconotide
Through the combination of tangential flow ultrafiltration and hybrid reverse phase chromatography columns, the problem of low sample purity and yield in ziconolide purification was solved, and the purity obtained was achieved with high efficiency and low cost ziconolide purification. The finished product of ziconotinoid with a yield of more than 99.8%, with a yield of 75.3%.
Patent Information
- Application Number
- CN202411400131.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-12-29
- Filing Date
- 2024-10-09
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art samples are low in purifying ziconolopeptide, low yield, and high cost, making it difficult to effectively remove impurities and fragment impurities.
The first ultrafiltration was performed using a tangential flow ultrafiltration system, followed by gradient elution of octadecylsilane-bonded silica gel hybrid filler and phosphate solution, combined with acetonitrile as mobile phase, and a hybrid reverse phase chromatography column was performed. Purification, and finally part of the solvent was removed by a rotary evaporator to obtain a high-purity ziconotide sample.
The high purity of ziconolopeptide (purity greater than 99.8%) and high yield (yield up to 75.3%) are achieved, while reducing the purification cost, improving the purification efficiency and the purity of the finished product.
Smart Images

Figure BDA0005075032870000011 
Figure BDA0005075032870000012 
Figure BDA0005075032870000041
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of peptide purification, in particular to a method for purifying ziconotide. Background Art
[0002] Chinese name: Ziconotide; English name: ziconotide; peptide sequence:
[0003]
[0004] The chemical structure is described as:
[0005]
[0006] Ziconotide (also known as SNX-111) is a neurotoxic peptide derived from the cone snail Corythuja spp. It is composed of 25 amino acids and three disulfide bonds. Together with other similar peptides, it is collectively referred to as conotoxins. Ziconotide can inhibit the activity of N-type calcium channels involved in pain signal transduction and is used to treat severe chronic pain that is refractory to other methods. It was approved for marketing by the FDA in 2004 and is the only calcium channel blocking peptide approved by the FDA.
[0007] In the solid phase synthesis of ziconotide, a variety of impurities that affect the purity and yield of the sample are produced in the synthesis. The purity and yield of the ziconotide sample separated by the existing purification technology are low. Summary of the invention
[0008] To overcome the deficiencies of the prior art, the present invention aims to provide a method for purifying ziconotide, which comprises a tangential flow ultrafiltration and a hybrid reverse phase chromatography column purification, thereby saving costs and improving the purity and yield of ziconotide.
[0009] In order to achieve the above object, the present invention adopts the following technical solution:
[0010] A method for purifying ziconotide comprises the following steps:
[0011] Step 1, pre-treating the crude ziconotide product to obtain a crude ziconotide peptide aqueous solution;
[0012] Step 2, using a tangential flow ultrafiltration system, using a membrane package with a cut-off of 1 kDa as the filter membrane, and pure water as the dialysate to perform the first ultrafiltration to remove impurities, and collect the fraction containing the ziconotide sample;
[0013] Step 3, using octadecylsilane bonded silica hybrid filler as the stationary phase, phosphate solution as mobile phase A, acetonitrile as mobile phase B, and a detection wavelength of 220 nm, performing gradient elution to collect the fraction containing the ziconotide sample;
[0014] Step 4: using octaalkylsilane bonded silica gel as the stationary phase, acetic acid as the mobile phase A, and acetonitrile as the mobile phase B.
[0015] The detection wavelength was 260 nm, salt conversion was performed, and the fraction containing the ziconotide sample was collected;
[0016] Step 5: Use a rotary evaporator with a water bath temperature of 30 to 35° C. and a vacuum degree of less than -0.09 MPa to remove part of the acetonitrile to obtain a ziconotide sample solution, which is acidic.
[0017] The aforementioned method for purifying ziconotide comprises step 1, pre-treating the crude ziconotide product to obtain a crude ziconotide peptide aqueous solution; the pre-treatment step comprises:
[0018] 1) dissolving the crude ziconotide product in water and a dilute ammonia solution to obtain a crude ziconotide peptide aqueous solution;
[0019] 2) Filter the ziconotide aqueous solution through a filter membrane to remove insoluble particles, and collect the filtrate for later use.
[0020] The aforementioned method for purifying ziconotide, step 2, using a tangential flow ultrafiltration system, a membrane package with a 1kDa cutoff as the filter membrane, and pure water as the dialysate to perform the first ultrafiltration to remove impurities, and collect the fraction containing the ziconotide sample; the membrane package is made of regenerated cellulose and has a molecular weight cutoff of 1kDa.
[0021] The aforementioned method for purifying ziconotide, step three, using octadecylsilane bonded silica hybrid filler as the stationary phase, phosphate solution as mobile phase A, acetonitrile as mobile phase B, detection wavelength of 220nm, gradient elution, and collecting the fraction containing the ziconotide sample; the preparation method of the phosphate solution is: take 1000ml of water and add 0.1% ammonia water, adjust the pH to 2.0 with phosphoric acid to obtain a phosphate solution.
[0022] The aforementioned method for purifying ziconotide, step 4, using octaalkylsilane bonded silica filler as the stationary phase, acetic acid as the mobile phase A, acetonitrile as the mobile phase B, the detection wavelength is 260nm, salt conversion is performed, and the fraction containing the ziconotide sample is collected; the preparation method of the acetic acid solution is: take 1000ml of water and add 10ml of acetic acid.
[0023] The aforementioned method for purifying ziconotide, step 5, using a rotary evaporator with a water bath temperature of 30 to 35° C. and a vacuum degree of less than -0.09 MPa to remove part of the acetonitrile to obtain a ziconotide sample solution, the sample solution is acidic.
[0024] Compared with the prior art, the present invention is beneficial in that:
[0025] 1. First use the tangential flow ultrafiltration system to remove most of the impurities and fragment impurities in ziconotide; it can greatly save time and reagent costs; it is highly efficient, and the purity of the collected samples is more than 92%.
[0026] 2. The chromatographic conditional gradient elution is performed by using octadecylsilane bonded silica gel hybrid filler as the stationary phase and phosphate solution as the mobile phase. Compared with other common chromatographic columns, the hybrid column has high separation efficiency and can remove impurities in the sample with similar physical and chemical properties to ziconotide. A single impurity sample with a purity of more than 99% can be obtained at one time, which reduces costs and improves the purity and yield of ziconotide finished products. DETAILED DESCRIPTION
[0027] The present invention is described in detail below with reference to specific embodiments.
[0028] A method for purifying ziconotide comprises the following steps:
[0029] Step 1, pre-treating the crude ziconotide product to obtain a crude ziconotide peptide aqueous solution;
[0030] The preprocessing steps include:
[0031] 1) dissolving the crude ziconotide product in water and a dilute ammonia solution to obtain a crude ziconotide peptide aqueous solution;
[0032] 2) Filter the ziconotide aqueous solution through a filter membrane to remove insoluble particles, and collect the filtrate for later use. Preferably, the filter membrane is a 0.22 μm filter membrane.
[0033] Step 2: Using a tangential flow ultrafiltration system, a membrane package with a cutoff of 1 kDa as the filter membrane and pure water as the dialysate to perform the first ultrafiltration to remove impurities, and collect the fraction containing the ziconotide sample; the membrane package is made of regenerated cellulose and has a molecular weight cutoff of 1 kDa.
[0034] Step 3, using octadecylsilane bonded silica hybrid filler as the stationary phase, phosphate solution as mobile phase A, acetonitrile as mobile phase B, and the detection wavelength of 220nm, gradient elution is performed to collect the fraction containing the ziconotide sample; the preparation method of the phosphate solution is: take 1000ml of water and add 0.1% ammonia water, and adjust the pH to 2.0 with phosphoric acid to obtain a phosphate solution.
[0035] Step 4: using octaalkylsilane bonded silica gel filler as the stationary phase, acetic acid as the mobile phase A, acetonitrile as the mobile phase B, and the detection wavelength at 260 nm, performing salt conversion and collecting the fraction containing the ziconotide sample.
[0036] Step 5: Use a rotary evaporator with a water bath temperature of 30 to 35° C. and a vacuum degree of less than -0.09 MPa to remove part of the acetonitrile to obtain a ziconotide sample solution, which is acidic.
[0037] In order to prove that the purification method of the present invention can remove impurities and obtain a high-purity, high-yield ziconotide finished product, a purification experiment was conducted using 3g, 8g, and 32g of crude ziconotide peptide samples using the present method. The experimental process is as follows:
[0038] Embodiment 1:
[0039] Get crude ziconotide
[0040] Sample treatment: Dissolve a sample containing 3 g of crude ziconotide peptide (crude peptide: 5.2 g) in water and dilute ammonia solution, and filter with a 0.22 μm filter membrane after complete dissolution. Collect the filtered crude ziconotide peptide aqueous solution for later use.
[0041] First step: tangential flow ultrafiltration purification
[0042] Chromatographic conditions: using a tangential flow ultrafiltration system; using a membrane package with a cutoff of 1 kDa as the filter membrane, pure water as the dialysate for the first ultrafiltration to remove impurities; the processing volume is 3 g, the membrane package area is 0.02 m2, the material is regenerated cellulose, the transmembrane pressure is 30 psi, and the fraction of the ziconotide sample is collected to obtain the first step sample solution of ziconotide.
[0043] Second step HPLC purification
[0044] Chromatographic conditions: chromatographic column with octadecylsilane bonded silica hybrid filler as stationary phase (30mm×250mm, 10μm); phosphate solution (1000ml water plus 1ml ammonia water, phosphoric acid adjusted to pH=2.0) as mobile phase A; acetonitrile as mobile phase B; flow rate of 10mL per minute; detection wavelength of 220nm; maximum sample loading of 0.5g. Elution was performed according to the elution gradient in the table below.
[0045]
[0046] The fraction of the ziconotide sample with a purity greater than 99.8% was collected. A portion of the acetonitrile was removed by a rotary evaporator at a water bath temperature of 30 to 35°C and a vacuum degree of less than -0.09 MPa. The solution was quantitatively determined to contain 2.30 g of ziconotide by a reference substance, and the yield was 76.7%.
[0047] Embodiment 2:
[0048] Get crude ziconotide
[0049] Sample treatment: Dissolve 8 g of crude ziconotide peptide (crude peptide: 13.9 g) in water and dilute ammonia solution, and filter with a 0.22 μm filter membrane after complete dissolution. Collect the filtered crude peptide aqueous solution for later use.
[0050] First step: tangential flow ultrafiltration purification
[0051] The first ultrafiltration was performed using a tangential flow ultrafiltration system; a membrane package with a cutoff of 1 kDa was used as the filter membrane, and pure water was used as the dialysate; the membrane package area was 0.1 m2, the processing volume was 8 g, the material was regenerated cellulose, the transmembrane pressure was 30 psi, and the fraction of the ziconotide sample was collected. The first step sample solution of ziconotide was obtained. The fraction of the ziconotide sample was collected. The first step sample solution of ziconotide was obtained.
[0052] Second step HPLC purification
[0053] Chromatographic conditions: chromatographic column with octadecylsilane bonded silica hybrid filler as stationary phase (50mm×250mm, 10μm); phosphate solution (1000ml water plus 1ml ammonia water, phosphoric acid adjusted to pH=2.0) as mobile phase A; acetonitrile as mobile phase B; flow rate of 50mL per minute; detection wavelength of 220nm; maximum sample loading of 1.4g. Elution was performed using the elution gradient shown in the table below.
[0054]
[0055] The fraction of the ziconotide sample with a purity greater than 99.8% was collected. A rotary evaporator was used to remove part of the acetonitrile at a water bath temperature of 30-35°C and a vacuum degree of less than -0.09 MPa. The solution was quantitatively determined to contain 5.80 g of ziconotide by reference, and the yield was 72.5%.
[0056] Embodiment 3:
[0057] Get crude ziconotide
[0058] Sample treatment: Dissolve a sample containing 32 g of crude ziconotide peptide (crude peptide: 55.5 g) in water and dilute ammonia solution, and filter with a 0.22 μm filter membrane after complete dissolution. Collect the filtered crude peptide aqueous solution for later use.
[0059] First step: tangential flow ultrafiltration purification
[0060] The first ultrafiltration was performed using a tangential flow ultrafiltration system; a membrane package with a cutoff of 1 kDa was used as the filter membrane, and pure water was used as the dialysate; the membrane package area was 0.1 m2, the maximum processing volume each time was 8 g, the material was regenerated cellulose, the transmembrane pressure was 30 psi, and the fraction of the ziconotide sample was collected to obtain the first step sample solution of ziconotide.
[0061] Second step HPLC purification
[0062] Chromatographic conditions: chromatographic column with octadecylsilane bonded silica gel hybrid filler as stationary phase (100mm×250mm, 10μm); phosphate solution (1000ml water plus 1ml ammonia water, phosphoric acid adjusted to pH=2.0) as mobile phase A; acetonitrile as mobile phase B; flow rate of 150mL per minute; detection wavelength of 220nm; maximum sample loading of 5.6g. Elution was performed according to the elution gradient in the table below.
[0063]
[0064]
[0065] The fraction of the ziconotide sample with a purity greater than 99.8% was collected. A rotary evaporator was used at a water bath temperature of 30 to 35°C and a vacuum degree of less than -0.09 MPa to remove part of the acetonitrile. The solution was quantitatively determined to contain 24.10 g of ziconotide by reference, and the yield was 75.3%.
[0066]
[0067] It can be seen from the three embodiments that the purity of the obtained ziconotide crude product is greater than 99.8%, the maximum single impurity is no more than 0.1%, and the number of impurities is no more than 4. The present invention provides a method for purifying ziconotide. The present invention is purified by a tangential flow ultrafiltration and a hybrid reverse phase chromatography. The purity of the sample obtained by the first tangential flow ultrafiltration is 92%, and the purity of the sample obtained by the second tangential flow ultrafiltration is 99%, which reduces the cost of purification and greatly improves the purity and yield of ziconotide. This is the conclusion drawn by the inventor through the HPLC graph of ziconotide after tangential flow ultrafiltration purification and the HPLC graph of ziconotide after reverse phase chromatography column purification.
[0068] The above shows and describes the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the above embodiments do not limit the present invention in any form, and any technical solution obtained by equivalent replacement or equivalent transformation falls within the protection scope of the present invention.
Claims
1. A method for purifying ziconotide, characterized in that: The steps include: Step 1, pre-treating the crude ziconotide product to obtain a crude ziconotide peptide aqueous solution; Step 2, using a tangential flow ultrafiltration system and pure water as a dialysate to perform a first ultrafiltration purification to remove impurities of the ziconotide fragment; Step 3, using octadecylsilane bonded silica filler as the stationary phase and phosphate solution as the mobile phase A; Acetonitrile was used as mobile phase B for purification to remove impurities with similar physical and chemical properties to ziconotide; Step 4, using octaalkylsilane bonded silica filler as the stationary phase, acetic acid as the mobile phase A, and acetonitrile as the mobile phase B, to perform salt conversion to obtain a ziconotide solution containing only acetate; Step 5, removing the solvent to obtain a ziconotide solution.
2. A method for purifying ziconotide according to claim 1, characterized in that: The pre-treatment step in step 1 includes: dissolving the crude ziconotide product in water and a dilute ammonia solution to obtain a crude ziconotide peptide aqueous solution; The ziconotide aqueous solution was filtered through a filter membrane to remove insoluble particles, and the filtrate was collected for later use.
3. A method for purifying ziconotide according to claim 1, characterized in that: Step 2: Using a tangential flow ultrafiltration system, a membrane package with a cutoff of 1 kDa as the filter membrane and pure water as the dialysate to perform the first ultrafiltration to remove impurities, and collect the fraction containing the ziconotide sample; the membrane package is made of regenerated cellulose and has a molecular weight cutoff of 1 kDa.
4. A method for purifying ziconotide according to claim 1, characterized in that: Step three, using octadecylsilane bonded silica filler as the stationary phase, phosphate solution as mobile phase A, acetonitrile as mobile phase B, and the detection wavelength of 220 nm, gradient elution is performed to collect the fraction containing the ziconotide sample; the preparation method of the phosphate solution is: take 1000 ml of water and add 0.1% ammonia water, and adjust the pH to 2.0 with phosphoric acid to obtain a phosphate solution.
5. A method for purifying ziconotide according to claim 1, characterized in that: In step 4, octaalkylsilane bonded silica filler is used as the stationary phase, acetic acid is used as the mobile phase A, acetonitrile is used as the mobile phase B, the detection wavelength is 260 nm, salt conversion is performed, and the fraction containing the ziconotide sample is collected; the preparation method of the acetic acid solution is: take 1000 ml of water and add 10 ml of acetic acid.
6. A method for purifying ziconotide according to claim 1, characterized in that: In step 5, a rotary evaporator is used to remove part of the acetonitrile at a water bath temperature of 30-35° C. and a vacuum degree of less than -0.09 MPa to obtain a ziconotide sample solution, which is acidic.
